Latest news:

Analysis of Follicum now published

On 25 November 2020, Aktiespararna published their analysis of Follicum on their website. The analysis can also be read on Follicum’s webpage. Read the analysis at Aktiespararna.se For further information, please contact: Jan Alenfall – CEO, Follicum AB Telephone: +46 (0)709 31 51 15 Email: info@follicum.com About Follicum AB Follicum AB (Spotlight: FOLLI) develops drugs […]

Sign up for our Newsletter

Follicum’s compliance with GDPR. Read more

Presentation BioStock Life Science Summit 2020, November 18

Hair growth

Our drug candidate FOL-005 has demonstrated increased hair growth on both healthy individuals and on patients with alopecia in two clinical phase II trials, which both demonstrated good safety and efficacy.

Read more

Diabetes

Follicums pre-clinical research has resulted in a new peptide class which increased the release of insulin on mice

Read more

Investors

We want to develop safe, effective and cost effective drugs, suitable for both men and women, that have minimal side effects

Read more

Press

News

Events